Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Hepatic copper and other trace mineral concentrations in dogs with hepatocellular carcinoma.

Harro CC, Smedley RC, Buchweitz JP, Langlois DK.

J Vet Intern Med. 2019 Sep;33(5):2193-2199. doi: 10.1111/jvim.15619. Epub 2019 Sep 7.

2.

Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection.

Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, Liang X, Mani S, Wenzel H, Townsend RR, Gilmore PE, Darsley MJ, Rasko DA, Fleckenstein JM.

NPJ Vaccines. 2019 Aug 28;4:37. doi: 10.1038/s41541-019-0131-7. eCollection 2019.

3.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2019 Jul 1;129(7):2980. doi: 10.1172/JCI130874. Epub 2019 Jul 1. No abstract available.

4.

Development of a novel multiplex electrochemiluminescent-based immunoassay to aid enterotoxigenic Escherichia coli vaccine development and evaluations.

Chakraborty S, Brubaker J, Harro C, Weirzba T, Sack D.

J Immunol Methods. 2019 Jul;470:6-14. doi: 10.1016/j.jim.2019.04.003. Epub 2019 Apr 18.

5.

Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.

Harro C, Louis Bourgeois A, Sack D, Walker R, DeNearing B, Brubaker J, Maier N, Fix A, Dally L, Chakraborty S, Clements JD, Saunders I, Darsley MJ.

Vaccine. 2019 Mar 28;37(14):1978-1986. doi: 10.1016/j.vaccine.2019.02.025. Epub 2019 Feb 21.

6.

Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.

Fernandes VC, Golubeva VA, Di Pietro G, Shields C, Amankwah K, Nepomuceno TC, de Gregoriis G, Abreu RBV, Harro C, Gomes TT, Silva RF, Suarez-Kurtz G, Couch FJ, Iversen ES, Monteiro ANA, Carvalho MA.

J Biol Chem. 2019 Apr 12;294(15):5980-5992. doi: 10.1074/jbc.RA118.005274. Epub 2019 Feb 14.

PMID:
30765603
7.

Comparing Balance Performance on Force Platform Measures in Individuals with Parkinson's Disease and Healthy Adults.

Harro CC, Kelch A, Hargis C, DeWitt A.

Parkinsons Dis. 2018 Dec 2;2018:6142579. doi: 10.1155/2018/6142579. eCollection 2018.

8.

Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, Liang X, Mani S, Wenzel H, Townsend RR, Gilmore PE, Darsley MJ, Rasko DA, Fleckenstein JM.

J Infect Dis. 2018 Sep 22;218(9):1436-1446. doi: 10.1093/infdis/jiy312.

9.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2018 Aug 1;128(8):3298-3311. doi: 10.1172/JCI97659. Epub 2018 Jun 25. Erratum in: J Clin Invest. 2019 Jul 1;129(7):2980.

10.

Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.

Chakraborty S, Harro C, DeNearing B, Brubaker J, Connor S, Maier N, Dally L, Flores J, Bourgeois AL, Walker R, Sack DA.

PLoS Negl Trop Dis. 2018 Apr 27;12(4):e0006442. doi: 10.1371/journal.pntd.0006442. eCollection 2018 Apr.

11.

Campylobacter jejuni transcriptional and genetic adaptation during human infection.

Crofts AA, Poly FM, Ewing CP, Kuroiwa JM, Rimmer JE, Harro C, Sack D, Talaat KR, Porter CK, Gutierrez RL, DeNearing B, Brubaker J, Laird RM, Maue AC, Jaep K, Alcala A, Tribble DR, Riddle MS, Ramakrishnan A, McCoy AJ, Davies BW, Guerry P, Trent MS.

Nat Microbiol. 2018 Apr;3(4):494-502. doi: 10.1038/s41564-018-0133-7. Epub 2018 Mar 27.

12.

Reliability and Validity of Computerized Force Platform Measures of Balance Function in Healthy Older Adults.

Harro CC, Garascia C.

J Geriatr Phys Ther. 2019 Jul/Sep;42(3):E57-E66. doi: 10.1519/JPT.0000000000000175.

PMID:
29324510
13.

Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, Double-Blind, Placebo-Controlled Trial.

Rimmer JE, Harro C, Sack DA, Talaat KR, Gutierrez RL, DeNearing B, Brubaker J, Laird RM, Poly F, Maue AC, Jaep K, Alcala A, Mochalova Y, Gariepy CL, Chakraborty S, Guerry P, Tribble DR, Porter CK, Riddle MS.

Clin Infect Dis. 2018 Apr 17;66(9):1435-1441. doi: 10.1093/cid/cix1014.

PMID:
29145631
14.

Dissecting genetic risk factors in breast cancer.

Harro CM, Monteiro AN.

Oncotarget. 2017 Feb 21;8(8):12540-12541. doi: 10.18632/oncotarget.15089. No abstract available.

15.

Reliability and Validity of Force Platform Measures of Balance Impairment in Individuals With Parkinson Disease.

Harro CC, Marquis A, Piper N, Burdis C.

Phys Ther. 2016 Dec;96(12):1955-1964. Epub 2016 Jul 14.

PMID:
27417165
16.

Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment.

Pop M, Paulson JN, Chakraborty S, Astrovskaya I, Lindsay BR, Li S, Bravo HC, Harro C, Parkhill J, Walker AW, Walker RI, Sack DA, Stine OC.

BMC Genomics. 2016 Jun 8;17:440. doi: 10.1186/s12864-016-2777-0.

17.

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, DeNearing B, Steinsland H, Tribble DR, Bourgeois AL.

PLoS One. 2016 Mar 3;11(3):e0149358. doi: 10.1371/journal.pone.0149358. eCollection 2016.

18.

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.

Chakraborty S, Harro C, DeNearing B, Bream J, Bauers N, Dally L, Flores J, Van de Verg L, Sack DA, Walker R.

Clin Vaccine Immunol. 2016 Apr 4;23(4):315-25. doi: 10.1128/CVI.00608-15. Print 2016 Apr.

19.

Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.

Yang WE, Suchindran S, Nicholson BP, McClain MT, Burke T, Ginsburg GS, Harro CD, Chakraborty S, Sack DA, Woods CW, Tsalik EL.

J Infect Dis. 2016 May 1;213(9):1495-504. doi: 10.1093/infdis/jiv593. Epub 2016 Jan 18.

20.

Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.

Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA.

Clin Vaccine Immunol. 2015 Nov 18;23(1):55-64. doi: 10.1128/CVI.00617-15. Print 2016 Jan.

21.

Global Regulator of Virulence A (GrvA) Coordinates Expression of Discrete Pathogenic Mechanisms in Enterohemorrhagic Escherichia coli through Interactions with GadW-GadE.

Morgan JK, Carroll RK, Harro CM, Vendura KW, Shaw LN, Riordan JT.

J Bacteriol. 2015 Nov 2;198(3):394-409. doi: 10.1128/JB.00556-15. Print 2016 Feb 1.

22.

Double-network gels and the toughness of terrestrial slug glue.

Wilks AM, Rabice SR, Garbacz HS, Harro CC, Smith AM.

J Exp Biol. 2015 Oct;218(Pt 19):3128-37. doi: 10.1242/jeb.128991. Epub 2015 Aug 14.

23.

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.

Fix AD, Harro C, McNeal M, Dally L, Flores J, Robertson G, Boslego JW, Cryz S.

Vaccine. 2015 Jul 17;33(31):3766-72. doi: 10.1016/j.vaccine.2015.05.024. Epub 2015 Jun 8.

24.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

25.

Examining the function in sitting test for validity, responsiveness, and minimal clinically important difference in inpatient rehabilitation.

Gorman SL, Harro CC, Platko C, Greenwald C.

Arch Phys Med Rehabil. 2014 Dec;95(12):2304-11. doi: 10.1016/j.apmr.2014.07.415. Epub 2014 Aug 24.

PMID:
25159714
26.

The effects of speed-dependent treadmill training and rhythmic auditory-cued overground walking on gait function and fall risk in individuals with idiopathic Parkinson's disease: a randomized controlled trial.

Harro CC, Shoemaker MJ, Frey OJ, Gamble AC, Harring KB, Karl KL, McDonald JD, Murray CJ, Tomassi EM, Van Dyke JM, VanHaistma RJ.

NeuroRehabilitation. 2014;34(3):557-72. doi: 10.3233/NRE-141051.

PMID:
24473249
27.

The effects of speed-dependent treadmill training and rhythmic auditory-cued overground walking on balance function, fall incidence, and quality of life in individuals with idiopathic Parkinson's disease: a randomized controlled trial.

Harro CC, Shoemaker MJ, Frey O, Gamble AC, Harring KB, Karl KL, McDonald JD, Murray CJ, VanDyke JM, Tomassi EM, VanHaitsma RJ.

NeuroRehabilitation. 2014;34(3):541-56. doi: 10.3233/NRE-141048.

PMID:
24473244
28.

Quantitative PCR and culture evaluation for enterotoxigenic Escherichia coli (ETEC) associated diarrhea in volunteers.

Lindsay BR, Chakraborty S, Harro C, Li S, Nataro JP, Sommerfelt H, Sack DA, Colin Stine O.

FEMS Microbiol Lett. 2014 Mar;352(1):25-31. doi: 10.1111/1574-6968.12362. Epub 2014 Jan 6.

29.

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD.

Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. doi: 10.1128/CVI.00364-12. Epub 2012 Oct 3.

30.

The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.

Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA.

Vaccine. 2012 Feb 21;30(9):1729-36. doi: 10.1016/j.vaccine.2011.12.045. Epub 2011 Dec 20.

PMID:
22192849
31.

Norovirus vaccine against experimental human Norwalk Virus illness.

Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM.

N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.

32.

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2118-27. doi: 10.1128/CVI.05342-11. Epub 2011 Oct 12.

33.

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA.

Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

34.

Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N.

Clin Vaccine Immunol. 2010 Dec;17(12):1868-74. doi: 10.1128/CVI.00356-10. Epub 2010 Oct 13.

35.

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA.

Vaccine. 2010 Jul 26;28(33):5407-13. doi: 10.1016/j.vaccine.2010.06.018. Epub 2010 Jun 17.

36.

Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles.

Shebl FM, Pinto LA, García-Piñeres A, Lempicki R, Williams M, Harro C, Hildesheim A.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):978-81. doi: 10.1158/1055-9965.EPI-10-0064. Epub 2010 Mar 23.

37.

In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.

Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD.

Vaccine. 2010 Apr 30;28(20):3602-8. doi: 10.1016/j.vaccine.2010.02.017. Epub 2010 Feb 24.

PMID:
20188175
38.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV.

J Infect Dis. 2010 Jan 1;201(1):132-41. doi: 10.1086/648591.

PMID:
19929694
39.

Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.

Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E; Merck V526-001 Study Group.

Clin Vaccine Immunol. 2009 Sep;16(9):1285-92. doi: 10.1128/CVI.00144-09. Epub 2009 Jul 15.

40.

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.

García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, Harro C, Lowy DR, Lempicki RA, Pinto LA.

J Immunol. 2009 Feb 1;182(3):1706-29.

41.

Taking an interdisciplinary team approach to rehabilitation after a TBI.

Hudson CM, Adams D, DeRose A, Harro CC.

Nursing. 2008 Jun;38 Suppl Therapy:7-11. doi: 10.1097/01.NURSE.0000343495.84713.13. No abstract available.

PMID:
19092535
42.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV; Merck V520-007/012 Study Teams.

AIDS Res Hum Retroviruses. 2009 Jan;25(1):103-14. doi: 10.1089/aid.2008.0212.

43.

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA.

Clin Vaccine Immunol. 2007 Aug;14(8):984-9. Epub 2007 Jun 27.

44.

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12.

45.

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network.

Vaccine. 2007 Jan 5;25(3):510-8. Epub 2006 Aug 10.

PMID:
17049679
46.

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A.

Virology. 2006 Sep 30;353(2):451-62. Epub 2006 Jul 24.

47.

Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.

Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, Harro C, Schwartz D, Berzofsky JA.

J Immunol. 2006 Mar 15;176(6):3753-9.

48.

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.

Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A.

Vaccine. 2005 May 20;23(27):3555-64.

PMID:
15855014
49.

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group.

J Infect Dis. 2005 Mar 1;191(5):654-65. Epub 2005 Jan 27.

PMID:
15688278
50.

Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.

Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, Koblin B, Marmor M, Bartholow BN, Popovic V; VAX004 Study Group.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1385-92.

PMID:
15483468

Supplemental Content

Support Center